{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:24:47Z","timestamp":1793802287686,"version":"4.6.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012551","name":"Sichuan Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012551","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.intimp.2026.117602","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:03:02Z","timestamp":1792728182000},"page":"117602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Targeted inhibition of HK2 expression in pancreatic ductal adenocarcinoma reprogrammes the immune microenvironment by regulating CCL5-mediated CD8+ T cell infiltration"],"prefix":"10.1016","volume":"191","author":[{"given":"Minglin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoding","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingquan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nengwen","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117602_bb0005","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/SLA.0000000000006320","article-title":"Perineural invasion is an important prognostic factor in patients with radically resected (R0) and node-negative (pN0) pancreatic Cancer","volume":"282","author":"Schouten","year":"2025","journal-title":"Ann. Surg."},{"key":"10.1016\/j.intimp.2026.117602_bb0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2026.117602_bb0015","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann. Surg."},{"key":"10.1016\/j.intimp.2026.117602_bb0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117602_bb0025","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.117602_bb0030","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.intimp.2026.117602_bb0035","first-page":"828","article-title":"Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother. (Hagerstown Md 1997)"},{"key":"10.1016\/j.intimp.2026.117602_bb0040","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117602_bb0045","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2026.117602_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152353","article-title":"Unlocking the therapeutic potential of polyphenols: promising advances and future directions in pancreatic cancer treatment","volume":"52","author":"Suhail","year":"2025","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.intimp.2026.117602_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152399","article-title":"Application prospects of tumor vaccines for pancreatic cancer: from TAAs to TSAs and combination strategies","volume":"52","author":"Lu","year":"2025","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.intimp.2026.117602_bb0060","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic Cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117602_bb0065","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.117602_bb0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117602_bb0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2026.117602_bb0080","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8(+) T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.117602_bb0085","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1053\/j.gastro.2018.12.038","article-title":"Broadening the impact of immunotherapy to pancreatic Cancer: challenges and opportunities","volume":"156","author":"Balachandran","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2026.117602_bb0090","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.117602_bb0095","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.tibs.2018.01.006","article-title":"Metabolic kinases moonlighting as protein kinases","volume":"43","author":"Lu","year":"2018","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.intimp.2026.117602_bb0100","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.molcel.2020.05.004","article-title":"Ectosomal PKM2 promotes HCC by inducing macrophage differentiation and remodeling the tumor microenvironment","volume":"78","author":"Hou","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.intimp.2026.117602_bb0105","first-page":"440","article-title":"CD73: a new target for tumor immunotherapy","volume":"18","author":"Si","year":"2023","journal-title":"Chin. Med. Biotechnol."},{"key":"10.1016\/j.intimp.2026.117602_bb0110","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2026.117602_bb0115","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1186\/s12885-022-10239-6","article-title":"High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+\/regulatory T-cell infiltration","volume":"22","author":"Kim","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2026.117602_bb0120","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","article-title":"Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma","volume":"29","author":"Peng","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2026.117602_bb0125","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s43018-020-00121-4","article-title":"Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer","volume":"1","author":"Steele","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.intimp.2026.117602_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104659","article-title":"Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma","volume":"25","author":"Chijimatsu","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.intimp.2026.117602_bb0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmet.2020.10.012","article-title":"Metabolic-pathway-based subtyping of triple-negative breast Cancer reveals potential therapeutic targets","volume":"33","author":"Gong","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2026.117602_bb0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.molcel.2023.02.022","article-title":"HK2: gatekeeping microglial activity by tuning glucose metabolism and mitochondrial functions","volume":"83","author":"Fang","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.intimp.2026.117602_bb0145","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid Tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117602_bb0150","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/cas.16204","article-title":"Hexokinase 2 nonmetabolic function-mediated phosphorylation of I\u03baB\u03b1 enhances pancreatic ductal adenocarcinoma progression","volume":"115","author":"Tong","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2026.117602_bb0155","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/2326-6066.CIR-16-0322","article-title":"T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma","volume":"5","author":"Stromnes","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2026.117602_bb0160","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.cmet.2022.08.002","article-title":"Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of I\u03baB\u03b1","volume":"34","author":"Guo","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2026.117602_bb0165","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10120-023-01405-1","article-title":"Gastric cancer mesenchymal stem cells via the CXCR2\/HK2\/PD-L1 pathway mediate immunosuppression","volume":"26","author":"Huang","year":"2023","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.intimp.2026.117602_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152338","article-title":"Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance","volume":"52","author":"Wu","year":"2025","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.intimp.2026.117602_bb0175","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in cancer: rationale and strategies","volume":"23","author":"Glorieux","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.117602_bb0180","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cmet.2024.03.015","article-title":"QDPR deficiency drives immune suppression in pancreatic cancer","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2026.117602_bb0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cr.2010.178","article-title":"Crosstalk of reactive oxygen species and NF-\u03baB signaling","volume":"21","author":"Morgan","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2026.117602_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2023.119573","article-title":"Reactive oxygen species and cell signaling. Review","volume":"1871","author":"Averill-Bates","year":"2024","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"10.1016\/j.intimp.2026.117602_bb0195","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2416221","article-title":"NRF3 suppresses the malignant progression of TNBC by promoting M1 polarization of macrophages via ROS\/HMGB1 axis","volume":"25","author":"Xing","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.intimp.2026.117602_bb0200","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","article-title":"The role of ROS in tumour development and progression","volume":"22","author":"Cheung","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2026.117602_bb0205","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature10189","article-title":"Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis","volume":"475","author":"DeNicola","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117602_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1476030","article-title":"NF-\u03baB signaling pathway in tumor microenvironment","volume":"15","author":"Cao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117602_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-014043","article-title":"Targeting AKR1B1 reprograms tumor-associated macrophages to enhance antitumor immunity","volume":"14","author":"Liu","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117602_bb0220","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.canlet.2014.09.003","article-title":"2-deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy","volume":"355","author":"Zhang","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.117602_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2015.46","article-title":"Energy disruptors: rising stars in anticancer therapy?","volume":"5","author":"Bost","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.intimp.2026.117602_bb0230","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3727\/096504016X14586627440192","article-title":"2-deoxy-d-glucose suppresses the in vivo antitumor efficacy of erlotinib in head and neck squamous cell carcinoma cells","volume":"24","author":"Sobhakumari","year":"2016","journal-title":"Oncol. Res."},{"key":"10.1016\/j.intimp.2026.117602_bb0235","doi-asserted-by":"crossref","first-page":"12347","DOI":"10.1007\/s13277-016-5089-8","article-title":"Synergistic increase in efficacy of a combination of 2-deoxy-D-glucose and cisplatin in normoxia and hypoxia: switch from autophagy to apoptosis","volume":"37","author":"Jalota","year":"2016","journal-title":"Tumour Biol.: J. Int. Soc. Oncodevelop. Biol. Med."},{"key":"10.1016\/j.intimp.2026.117602_bb0240","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0304-3835(01)00667-X","article-title":"Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase","volume":"173","author":"Ko","year":"2001","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.117602_bb0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10863-015-9612-1","article-title":"Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer","volume":"47","author":"Sun","year":"2015","journal-title":"J. Bioenerg. Biomembr."},{"key":"10.1016\/j.intimp.2026.117602_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113988","article-title":"3-bromopyruvate regulates the status of glycolysis and BCNU sensitivity in human hepatocellular carcinoma cells","volume":"177","author":"Sun","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117602_bb0255","first-page":"4977","article-title":"3-bromopyruvate inhibits pancreatic tumor growth by stalling glycolysis, and dismantling mitochondria in a syngeneic mouse model","volume":"12","author":"Roy","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117602_bb0260","first-page":"550","article-title":"Progress in research of targeting cancer glycolysis pathway for anticancer therapy","volume":"23","author":"Yan","year":"2014","journal-title":"Chin. J. New Drugs"},{"key":"10.1016\/j.intimp.2026.117602_bb0265","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.pharep.2015.11.007","article-title":"Anticancer agent 3-bromopyruvic acid forms a conjugate with glutathione","volume":"68","author":"Sadowska-Bartosz","year":"2016","journal-title":"Pharmacol. Rep.: PR"},{"key":"10.1016\/j.intimp.2026.117602_bb0270","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12672-025-02320-w","article-title":"Inhibiting glycolysis facilitated checkpoint blockade therapy for triple-negative breast cancer","volume":"16","author":"Li","year":"2025","journal-title":"Discov. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926014505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926014505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:24:48Z","timestamp":1793798688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926014505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":54,"alternative-id":["S1567576926014505"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117602","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted inhibition of HK2 expression in pancreatic ductal adenocarcinoma reprogrammes the immune microenvironment by regulating CCL5-mediated CD8+ T cell infiltration","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117602"}}